The size of the in vitro diagnostics (IVD) market is estimated at $100.96 billion in 2025, and is expected to reach $132.71 billion by 2030. Researchers attribute this growth to these key factors:1
For diagnostic solutions providers, this means the industry is becoming highly competitive. Innovation is key to staying ahead of the curve. Here’s how Medix Biochemica cultivates innovation to empower our IVD customers.2
Continuous innovation is essential to meet the ever-changing demands of our rapidly growing industry. By fostering innovation, Medix Biochemica helps customers stay at the forefront of diagnostic technology.2
Our R&D professionals have decades of experience in the development of critical raw materials for diagnostic applications. With one in every five Medix Biochemica employees dedicated to the design and development of new products, we’re able to stay at the cutting edge of the IVD industry, with solutions ranging from native and recombinant antibodies and antigens to molecular diagnostic reagents.3
Contact our team today to discuss your IVD needs and establish an innovative partnership with Medix Biochemica
Developing and engineering monoclonal antibodies
We’ve been pioneering monoclonal antibody development since the 1980s. We have world-leading expertise in developing novel antibodies for all types of molecules relevant in IVD, with both mouse hybridoma and phage display technologies.3
Our R&D specialists also have thorough knowledge of - and experience in - adapting antibody-producing cell lines to develop industrial-scale animal-free manufacturing processes.3
These innovations are possible because our product development department uses state-of-the-art recombinant technologies to develop engineered antibodies:3Purifying native proteins
Native proteins must be purified in order to:2Our R&D team has developed fully scalable processes for purifying native proteins from a range of human and animal sources. We also use cutting-edge extraction and chromatography methods to develop purification and enrichment protocols for native enzymes, antigens and other proteins, which is especially useful in cases where the source material has low levels of the target protein.3
Developing recombinant proteins
Unlike native proteins, recombinant proteins are manufactured by genetically engineering the host cells. These proteins can be used in calibrator and control products and are also critical raw materials in serology tests.2
We develop recombinant antigens using both bacterial and mammalian expression hosts, for optimal expression and functionality.3
Producing molecular diagnostic reagents
By detecting and amplifying specific DNA or RNA sequences associated with various diseases, molecular diagnostic reagents play a crucial role in diagnosing infectious diseases, genetic disorders and other medical conditions.2,4
Medix Biochemica produces a wide range of molecular reagents, including unique engineered polymerases and master mixes.3
Product characterization
Extensive quality control and product validation helps us ensure the correct, consistently performing and high-quality product is delivered each time we produce it. This ensures our customers’ tests deliver accurate and reliable results for patients every time as well. These results play a crucial role in diagnosing medical conditions, guiding treatment and monitoring diseases.2,5
Using a comprehensive selection of tools in our R&D laboratories, we characterize native and recombinant proteins and monoclonal antibodies, intensively studying their biological and functional properties via:3Our goal is to provide our customers with the latest and most effective materials, to enhance their diagnostic capabilities. Having Medix Biochemica as their innovative IVD raw materials and solutions partner helps our customers stay current with market trends and changing conditions:2
If you’re committed to staying ahead of the curve by driving innovation in the IVD industry, join forces with Medix Biochemica as your partner in diagnostic solutions.
References: